Bibliographical noteFunding Information:
The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) was funded totally (2000–04) and partially (2005–10) by the Department of Health (England) and by Public Health England. DML has received personal fees from Allecra, Discuva; Pfizer, Curetis, Cycle Pharma, Cubist, Alere, Bioversys, Forest, Tetraphase, Wockhardt, Shionogi, and AOP Orphan; grants and personal fees from Achaogen, Adenium, Meiji, and AstraZeneca; grants, personal fees, and other support from GlaxoSmithKline; personal fees and non-financial support from Bruker; grants from VenatoRx, Merck, and Rokitan; and other support from Perkin Elmer. CAI has received funding from Merck for testing alternative antimicrobial agents. All other authors declare that they have no conflicts of interest.